Evaluation of clinical outcomes of anidulafungin for the treatment of candidemia in hospitalized critically ill patients with obesity: A multicenter, retrospective cohort study

Autor: Yazed Saleh Alsowaida, Khalid Al Sulaiman, Ahmad J. Mahrous, Aisha Alharbi, Nisrin Bifari, Walaa A. Alshahrani, Thamer A. Almangour, Nader Damfu, Aseel A. Banamah, Raghad R. Abu Raya, Raghad A. Sadawi, Arwa Alharbi, Ahmed Alsolami, Yahya Essa, Alaa Ghaze Almagthali, Shahad F. Alhejaili, Wed A. Qawwas, Ghaida Salamah Alharbi, Atheer Suleiman Alkeraidees, Afnan Alshomrani, Manal A. Aljohani, Ohoud Aljuhani
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: International Journal of Infectious Diseases, Vol 148, Iss , Pp 107234- (2024)
Druh dokumentu: article
ISSN: 1201-9712
DOI: 10.1016/j.ijid.2024.107234
Popis: Objectives: To evaluate the clinical outcomes of anidulafungin for candidemia treatment in critically ill patients with obesity. Methods: A multicenter, retrospective cohort study was conducted in Saudi Arabia for critically ill adults with candidemia who received anidulafungin. Patients with obesity have a body mass index ≥30 kg/m2. The primary outcome was the clinical cure rate. Results: A total of 146 patients were included, 64 of whom were obese. There were no statistically significant differences in the clinical cure rate (P = 0.63), microbiological cure rate (P = 0.27), or the median time for a clinical cure (P = 0.13) for patients with obesity compared to non-obese patients. The median time for a microbiological cure was longer in non-obese patients than in patients with obesity (P = 0.04). The median hospital length of stay and the median mechanical ventilation durations were numerically longer in patients with obesity. Conclusions: Clinical and microbiological cure rates and time for clinical cure were statistically similar for both groups. Considering the study's limitations (especially with a small sample size), it is uncertain if patients with obesity have similar effectiveness to non-obese patients. Future studies with larger sample sizes are warranted to evaluate if obesity negatively impacts anidulafungin's clinical outcomes for candidemia.
Databáze: Directory of Open Access Journals